Mast Cell Activation and Cardiovascular Dysfunction
Mast cell activation syndrome (MCAS) frequently co-occurs with POTS and ME/CFS, forming part of the βSeptadβ of overlapping conditions. The cardiovascular effects of mast cell degranulation provide a mechanistic link between immune activation and hemodynamic instability.
1 Cardiovascular Mediators of Mast Cell Activation
Mast cells release multiple vasoactive mediators upon degranulation:
- Histamine: Causes vasodilation through H1 and H2 receptor activation on vascular smooth muscle, increasing vascular permeability and contributing to hypotension
- Prostaglandin D2: Potent vasodilator that may contribute to flushing and hypotensive episodes
- Tryptase: Serine protease that can activate protease-activated receptors on endothelial cells, potentially contributing to endothelial dysfunction
- Platelet-activating factor (PAF): Causes vasodilation, increases vascular permeability, and promotes platelet aggregation
- Heparin: Released during degranulation, may contribute to bleeding tendency and affect coagulation
During mast cell degranulation episodes, the sudden release of vasodilatory mediators can produce acute hypotensive episodes, flushing, and tachycardia. When mast cell activation is chronic and low-grade, the cumulative effect may include sustained endothelial dysfunction and impaired vascular reactivity.
2 The MCAS-POTS Connection
The relationship between MCAS and POTS is bidirectional. Mast cell mediators, particularly histamine, cause peripheral vasodilation that exacerbates venous pooling during orthostatic stress. Conversely, orthostatic stress may trigger mast cell degranulation in susceptible individuals, creating a feed-forward loop. This bidirectional interaction exemplifies the reinforcing pathophysiological cycles discussed in Section Unifying Mechanisms Across Systems of Chapter Integrative Models and Multi-System Pathophysiology.
Novak et al. documented that mast cell disorder patients universally showed dysautonomia when combining sympathetic, parasympathetic, and sudomotor testing (Novak et al. 2022). The same patients showed 20β24% reduction in orthostatic cerebral blood flow, directly linking mast cell activation to cerebral hypoperfusion during standing.
The high prevalence of small fiber neuropathy (80%) in mast cell disorder patients (Novak et al. 2022) suggests that mast cell mediators may directly damage autonomic nerve fibers or that both findings reflect a common underlying autoimmune process. Tryptase and other mast cell proteases can cleave components of the extracellular matrix and potentially damage nerve terminals.
3 Therapeutic Implications
The mast cell-cardiovascular connection has therapeutic implications. H1 antihistamines (cetirizine, loratadine, rupatadine) and H2 blockers (famotidine) may improve orthostatic symptoms in patients with concurrent MCAS. Mast cell stabilizers (cromolyn sodium, ketotifen) may provide broader suppression of mediator release. In patients with ME/CFS and prominent flushing, episodic tachycardia, or symptom fluctuation temporally associated with meals or environmental triggers, evaluation for MCAS should be considered, and empiric antihistamine therapy may be warranted.